Could G1 Therapeutics, Inc. (GTHX) Go Down After Achieving All Time High?

March 21, 2018 - By Michael Collier

The stock of G1 Therapeutics, Inc. (NASDAQ:GTHX) reached all time high today, Mar, 21 and still has $44.68 target or 7.00 % above today’s $41.76 share price. This indicates more upside for the $1.35B company. This technical setup was reported by If the $44.68 PT is reached, the company will be worth $94.57M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 3.49% or $1.41 during the last trading session, reaching $41.76. About 299,993 shares traded or 58.11% up from the average. G1 Therapeutics, Inc. (NASDAQ:GTHX) has 0.00% since March 21, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await G1 Therapeutics, Inc. (NASDAQ:GTHX) to report earnings on May, 16. After $-0.60 actual EPS reported by G1 Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 6.67 % negative EPS growth.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. The company has market cap of $1.35 billion. It is developing trilaciclib, an intravenous cyclin-dependent kinases 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. It currently has negative earnings. The firm has a clinical trial collaboration agreement with AstraZeneca to evaluate AstraZeneca's epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Tagrisso (osimertinib) in combination with oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer; and a research partnership GeneCentric Therapeutics, Inc. to identify subtypes of lung cancer where the compound is likely to be efficacious.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.